Research programme: STAT6 transcription factor inhibitors - Recludix Pharma
Latest Information Update: 30 Jul 2023
Price :
$50 *
At a glance
- Originator Recludix Pharma
- Class Anti-inflammatories; Antineoplastics; Protein diagnostics
- Mechanism of Action STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Inflammation
Most Recent Events
- 20 Jul 2023 Recludix Pharma and Sanofi agree to co-develop STAT6 transcription factor inhibitors for multiple immunological and inflammatory indications
- 27 Oct 2022 Early research in Cancer in USA (unspecified route), before October 2022
- 27 Oct 2022 Early research in Inflammation in USA (unspecified route), before October 2022